ESR1 and breast cancer: While much discussion has focused on the prevalence of hormone receptor negative cancers (particularly TNBC) among black women as a major driver of racial/ethnic disparities in breast cancer survival [58, 68], it is evident that there are additional barriers to survival for black women with ER+ or PR+ disease despite availability of targeted therapy.